Market Analysis and Insights: Global Oncology Based Molecular Diagnostic Market
The global Oncology Based Molecular Diagnostic market is projected to grow from US$ million in 2023 to US$ million by 2029, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for Oncology Based Molecular Diagnostic is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The China market for Oncology Based Molecular Diagnostic is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The Europe market for Oncology Based Molecular Diagnostic is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global key companies of Oncology Based Molecular Diagnostic include Abbott, Bayer Healthcare, Beckton Dickinson, Cepheid, Dako, Hologic, Qiagen, Roche and Siemens Healthineers, etc. in 2022, the global top five players had a share approximately % in terms of revenue.
Report Includes
This report presents an overview of global market for Oncology Based Molecular Diagnostic market size. Analyses of the global market trends, with historic market revenue data for 2018 - 2022, estimates for 2023, and projections of CAGR through 2029.
This report researches the key producers of Oncology Based Molecular Diagnostic, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Oncology Based Molecular Diagnostic, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Oncology Based Molecular Diagnostic revenue, market share and industry ranking of main companies, data from 2018 to 2023. Identification of the major stakeholders in the global Oncology Based Molecular Diagnostic market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, revenue, and growth rate, from 2018 to 2029. Evaluation and forecast the market size for Oncology Based Molecular Diagnostic revenue, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Abbott, Bayer Healthcare, Beckton Dickinson, Cepheid, Dako, Hologic, Qiagen, Roche and Siemens Healthineers, etc.
By Company
Abbott
Bayer Healthcare
Beckton Dickinson
Cepheid
Dako
Hologic
Qiagen
Roche
Siemens Healthineers
Sysmex
Segment by Type
Instruments
Reagents
Segment by Application
Breast Cancer
Prostate Cancer
Colorectal Cancer
Cervical Cancer
Liver Cancer
Lung Cancer
Blood Cancer
Kidney Cancer
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East, Africa, and Latin America
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Oncology Based Molecular Diagnostic in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Oncology Based Molecular Diagnostic companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America by type, by application and by country, revenue for each segment.
Chapter 7: Europe by type, by application and by country, revenue for each segment.
Chapter 8: China by type and by application revenue for each segment.
Chapter 9: Asia (excluding China) by type, by application and by region, revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by type, by application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Oncology Based Molecular Diagnostic revenue, gross margin, and recent development, etc.
Chapter 12: Analyst's Viewpoints/Conclusions
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Oncology Based Molecular Diagnostic Market Size Growth Rate by Type, 2018 VS 2022 VS 2029
1.2.2 Instruments
1.2.3 Reagents
1.3 Market by Application
1.3.1 Global Oncology Based Molecular Diagnostic Market Size Growth Rate by Application, 2018 VS 2022 VS 2029
1.3.2 Breast Cancer
1.3.3 Prostate Cancer
1.3.4 Colorectal Cancer
1.3.5 Cervical Cancer
1.3.6 Liver Cancer
1.3.7 Lung Cancer
1.3.8 Blood Cancer
1.3.9 Kidney Cancer
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Oncology Based Molecular Diagnostic Market Perspective (2018-2029)
2.2 Global Oncology Based Molecular Diagnostic Growth Trends by Region
2.2.1 Oncology Based Molecular Diagnostic Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Oncology Based Molecular Diagnostic Historic Market Size by Region (2018-2023)
2.2.3 Oncology Based Molecular Diagnostic Forecasted Market Size by Region (2024-2029)
2.3 Oncology Based Molecular Diagnostic Market Dynamics
2.3.1 Oncology Based Molecular Diagnostic Industry Trends
2.3.2 Oncology Based Molecular Diagnostic Market Drivers
2.3.3 Oncology Based Molecular Diagnostic Market Challenges
2.3.4 Oncology Based Molecular Diagnostic Market Restraints
3 Competition Landscape by Key Players
3.1 Global Revenue Oncology Based Molecular Diagnostic by Players
3.1.1 Global Oncology Based Molecular Diagnostic Revenue by Players (2018-2023)
3.1.2 Global Oncology Based Molecular Diagnostic Revenue Market Share by Players (2018-2023)
3.2 Global Oncology Based Molecular Diagnostic Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of Oncology Based Molecular Diagnostic, Ranking by Revenue, 2021 VS 2022 VS 2023
3.4 Global Oncology Based Molecular Diagnostic Market Concentration Ratio
3.4.1 Global Oncology Based Molecular Diagnostic Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Oncology Based Molecular Diagnostic Revenue in 2022
3.5 Global Key Players of Oncology Based Molecular Diagnostic Head office and Area Served
3.6 Global Key Players of Oncology Based Molecular Diagnostic, Product and Application
3.7 Global Key Players of Oncology Based Molecular Diagnostic, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Oncology Based Molecular Diagnostic Breakdown Data by Type
4.1 Global Oncology Based Molecular Diagnostic Historic Market Size by Type (2018-2023)
4.2 Global Oncology Based Molecular Diagnostic Forecasted Market Size by Type (2024-2029)
5 Oncology Based Molecular Diagnostic Breakdown Data by Application
5.1 Global Oncology Based Molecular Diagnostic Historic Market Size by Application (2018-2023)
5.2 Global Oncology Based Molecular Diagnostic Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Oncology Based Molecular Diagnostic Market Size (2018-2029)
6.2 North America Oncology Based Molecular Diagnostic Market Size by Type
6.2.1 North America Oncology Based Molecular Diagnostic Market Size by Type (2018-2023)
6.2.2 North America Oncology Based Molecular Diagnostic Market Size by Type (2024-2029)
6.2.3 North America Oncology Based Molecular Diagnostic Market Share by Type (2018-2029)
6.3 North America Oncology Based Molecular Diagnostic Market Size by Application
6.3.1 North America Oncology Based Molecular Diagnostic Market Size by Application (2018-2023)
6.3.2 North America Oncology Based Molecular Diagnostic Market Size by Application (2024-2029)
6.3.3 North America Oncology Based Molecular Diagnostic Market Share by Application (2018-2029)
6.4 North America Oncology Based Molecular Diagnostic Market Size by Country
6.4.1 North America Oncology Based Molecular Diagnostic Market Size by Country: 2018 VS 2022 VS 2029
6.4.2 North America Oncology Based Molecular Diagnostic Market Size by Country (2018-2023)
6.4.3 North America Oncology Based Molecular Diagnostic Market Size by Country (2024-2029)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe Oncology Based Molecular Diagnostic Market Size (2018-2029)
7.2 Europe Oncology Based Molecular Diagnostic Market Size by Type
7.2.1 Europe Oncology Based Molecular Diagnostic Market Size by Type (2018-2023)
7.2.2 Europe Oncology Based Molecular Diagnostic Market Size by Type (2024-2029)
7.2.3 Europe Oncology Based Molecular Diagnostic Market Share by Type (2018-2029)
7.3 Europe Oncology Based Molecular Diagnostic Market Size by Application
7.3.1 Europe Oncology Based Molecular Diagnostic Market Size by Application (2018-2023)
7.3.2 Europe Oncology Based Molecular Diagnostic Market Size by Application (2024-2029)
7.3.3 Europe Oncology Based Molecular Diagnostic Market Share by Application (2018-2029)
7.4 Europe Oncology Based Molecular Diagnostic Market Size by Country
7.4.1 Europe Oncology Based Molecular Diagnostic Market Size by Country: 2018 VS 2022 VS 2029
7.4.2 Europe Oncology Based Molecular Diagnostic Market Size by Country (2018-2023)
7.4.3 Europe Oncology Based Molecular Diagnostic Market Size by Country (2024-2029)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 China
8.1 China Oncology Based Molecular Diagnostic Market Size (2018-2029)
8.2 China Oncology Based Molecular Diagnostic Market Size by Type
8.2.1 China Oncology Based Molecular Diagnostic Market Size by Type (2018-2023)
8.2.2 China Oncology Based Molecular Diagnostic Market Size by Type (2024-2029)
8.2.3 China Oncology Based Molecular Diagnostic Market Share by Type (2018-2029)
8.3 China Oncology Based Molecular Diagnostic Market Size by Application
8.3.1 China Oncology Based Molecular Diagnostic Market Size by Application (2018-2023)
8.3.2 China Oncology Based Molecular Diagnostic Market Size by Application (2024-2029)
8.3.3 China Oncology Based Molecular Diagnostic Market Share by Application (2018-2029)
9 Asia (excluding China)
9.1 Asia Oncology Based Molecular Diagnostic Market Size (2018-2029)
9.2 Asia Oncology Based Molecular Diagnostic Market Size by Type
9.2.1 Asia Oncology Based Molecular Diagnostic Market Size by Type (2018-2023)
9.2.2 Asia Oncology Based Molecular Diagnostic Market Size by Type (2024-2029)
9.2.3 Asia Oncology Based Molecular Diagnostic Market Share by Type (2018-2029)
9.3 Asia Oncology Based Molecular Diagnostic Market Size by Application
9.3.1 Asia Oncology Based Molecular Diagnostic Market Size by Application (2018-2023)
9.3.2 Asia Oncology Based Molecular Diagnostic Market Size by Application (2024-2029)
9.3.3 Asia Oncology Based Molecular Diagnostic Market Share by Application (2018-2029)
9.4 Asia Oncology Based Molecular Diagnostic Market Size by Region
9.4.1 Asia Oncology Based Molecular Diagnostic Market Size by Region: 2018 VS 2022 VS 2029
9.4.2 Asia Oncology Based Molecular Diagnostic Market Size by Region (2018-2023)
9.4.3 Asia Oncology Based Molecular Diagnostic Market Size by Region (2024-2029)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
9.4.9 Australia
10 Middle East, Africa, and Latin America
10.1 Middle East, Africa, and Latin America Oncology Based Molecular Diagnostic Market Size (2018-2029)
10.2 Middle East, Africa, and Latin America Oncology Based Molecular Diagnostic Market Size by Type
10.2.1 Middle East, Africa, and Latin America Oncology Based Molecular Diagnostic Market Size by Type (2018-2023)
10.2.2 Middle East, Africa, and Latin America Oncology Based Molecular Diagnostic Market Size by Type (2024-2029)
10.2.3 Middle East, Africa, and Latin America Oncology Based Molecular Diagnostic Market Share by Type (2018-2029)
10.3 Middle East, Africa, and Latin America Oncology Based Molecular Diagnostic Market Size by Application
10.3.1 Middle East, Africa, and Latin America Oncology Based Molecular Diagnostic Market Size by Application (2018-2023)
10.3.2 Middle East, Africa, and Latin America Oncology Based Molecular Diagnostic Market Size by Application (2024-2029)
10.3.3 Middle East, Africa, and Latin America Oncology Based Molecular Diagnostic Market Share by Application (2018-2029)
10.4 Middle East, Africa, and Latin America Oncology Based Molecular Diagnostic Market Size by Country
10.4.1 Middle East, Africa, and Latin America Oncology Based Molecular Diagnostic Market Size by Country: 2018 VS 2022 VS 2029
10.4.2 Middle East, Africa, and Latin America Oncology Based Molecular Diagnostic Market Size by Country (2018-2023)
10.4.3 Middle East, Africa, and Latin America Oncology Based Molecular Diagnostic Market Size by Country (2024-2029)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Saudi Arabia
10.4.8 Israel
10.4.9 GCC Countries
11 Key Players Profiles
11.1 Abbott
11.1.1 Abbott Company Details
11.1.2 Abbott Business Overview
11.1.3 Abbott Oncology Based Molecular Diagnostic Introduction
11.1.4 Abbott Revenue in Oncology Based Molecular Diagnostic Business (2018-2023)
11.1.5 Abbott Recent Developments
11.2 Bayer Healthcare
11.2.1 Bayer Healthcare Company Details
11.2.2 Bayer Healthcare Business Overview
11.2.3 Bayer Healthcare Oncology Based Molecular Diagnostic Introduction
11.2.4 Bayer Healthcare Revenue in Oncology Based Molecular Diagnostic Business (2018-2023)
11.2.5 Bayer Healthcare Recent Developments
11.3 Beckton Dickinson
11.3.1 Beckton Dickinson Company Details
11.3.2 Beckton Dickinson Business Overview
11.3.3 Beckton Dickinson Oncology Based Molecular Diagnostic Introduction
11.3.4 Beckton Dickinson Revenue in Oncology Based Molecular Diagnostic Business (2018-2023)
11.3.5 Beckton Dickinson Recent Developments
11.4 Cepheid
11.4.1 Cepheid Company Details
11.4.2 Cepheid Business Overview
11.4.3 Cepheid Oncology Based Molecular Diagnostic Introduction
11.4.4 Cepheid Revenue in Oncology Based Molecular Diagnostic Business (2018-2023)
11.4.5 Cepheid Recent Developments
11.5 Dako
11.5.1 Dako Company Details
11.5.2 Dako Business Overview
11.5.3 Dako Oncology Based Molecular Diagnostic Introduction
11.5.4 Dako Revenue in Oncology Based Molecular Diagnostic Business (2018-2023)
11.5.5 Dako Recent Developments
11.6 Hologic
11.6.1 Hologic Company Details
11.6.2 Hologic Business Overview
11.6.3 Hologic Oncology Based Molecular Diagnostic Introduction
11.6.4 Hologic Revenue in Oncology Based Molecular Diagnostic Business (2018-2023)
11.6.5 Hologic Recent Developments
11.7 Qiagen
11.7.1 Qiagen Company Details
11.7.2 Qiagen Business Overview
11.7.3 Qiagen Oncology Based Molecular Diagnostic Introduction
11.7.4 Qiagen Revenue in Oncology Based Molecular Diagnostic Business (2018-2023)
11.7.5 Qiagen Recent Developments
11.8 Roche
11.8.1 Roche Company Details
11.8.2 Roche Business Overview
11.8.3 Roche Oncology Based Molecular Diagnostic Introduction
11.8.4 Roche Revenue in Oncology Based Molecular Diagnostic Business (2018-2023)
11.8.5 Roche Recent Developments
11.9 Siemens Healthineers
11.9.1 Siemens Healthineers Company Details
11.9.2 Siemens Healthineers Business Overview
11.9.3 Siemens Healthineers Oncology Based Molecular Diagnostic Introduction
11.9.4 Siemens Healthineers Revenue in Oncology Based Molecular Diagnostic Business (2018-2023)
11.9.5 Siemens Healthineers Recent Developments
11.10 Sysmex
11.10.1 Sysmex Company Details
11.10.2 Sysmex Business Overview
11.10.3 Sysmex Oncology Based Molecular Diagnostic Introduction
11.10.4 Sysmex Revenue in Oncology Based Molecular Diagnostic Business (2018-2023)
11.10.5 Sysmex Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Abbott
Bayer Healthcare
Beckton Dickinson
Cepheid
Dako
Hologic
Qiagen
Roche
Siemens Healthineers
Sysmex
*If Applicable.